Puricemia

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Puricemia

This overview defines the fundamental identity, classification, and general purpose of Puricemia, strictly excluding information on dosage, administration, side effects, or specific diseases.

Property Description
Active ingredient Allopurinol
Form Tablets
Pharmacological class Xanthine Oxidase Inhibitor
Common use Hyperuricemia management
Origin Synthetic compound

What Type of Medicine is Puricemia?

Puricemia is a prescription-only medicine defined as an antihyperuricemic agent, classified specifically within the drug group known as Xanthine Oxidase Inhibitors. The medication's active ingredient, Allopurinol, is a synthetic compound that is manufactured chemically rather than being derived from natural sources. This category of drug is essential for controlling the body's uric acid levels, a purpose that is clinically recognized for its significance in preventing chronic metabolic complications. This supports the drug's role in the long-term, stable management of metabolic excess.


Composition, Form, and General Purpose

The core therapeutic activity of Puricemia resides in its sole active ingredient, Allopurinol, making it a single-ingredient product. This substance plays a role in modulating purine catabolism. This medicine is most commonly supplied in the form of tablets designed for oral administration, utilizing pharmaceutical excipients for structural integrity. The precise physiological action involves blocking the xanthine oxidase enzyme, which prevents the body from producing excessive uric acid from other compounds. This inhibitory action consistently achieves reliable reductions in serum urate concentrations in patients. This process results in a controlled hypouricemic effect, serving the general therapeutic purpose of addressing the underlying chemical imbalance and providing metabolic maintenance.

What side effects are possible with Puricemia?

Possible Side Effects and Safety Information: Puricemia

The safety profile of Puricemia, which contains the active ingredient Allopurinol, is formally documented according to regulatory frequency and System-Organ-Class (SOC) classifications. The most Common adverse reaction is the appearance of a skin rash, which is categorized under Skin and Subcutaneous Tissue Disorders.

Official Regulatory Classifications

Adverse events are categorized by frequency, which includes Uncommon events like hypersensitivity reactions and abnormal liver function tests, and Rare events such as hepatitis and gastrointestinal issues like vomiting and nausea. The medicine's safety data highlights potential effects across several organ systems, including Hepatobiliary Disorders, Gastrointestinal Disorders, and Blood and Lymphatic System Disorders.

Serious Reactions and Safety Context

Regulatory sources emphasize the risk of Severe Cutaneous Adverse Reactions (SCARs), which are classified as rare but life-threatening conditions. These include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The risk of these severe hypersensitivity reactions is officially noted to be higher during the initial months of therapy.

Population-specific safety considerations documented in official labeling address patients with renal impairment. Because the medicine is primarily excreted by the kidneys, regulatory documents state that a dose adjustment is required for this group to mitigate the risk of adverse outcomes, particularly hypersensitivity. The medicine is strictly contraindicated in individuals with a documented history of severe hypersensitivity to Allopurinol. Furthermore, the label includes high-level safety notes on the potential for severe myelosuppression when used concurrently with certain other medications, mandating a dose change for the co-administered drug.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Puricemia (Allopurinol) strictly defines overdose manifestations and the necessary emergency response. Acute overdose following massive ingestion is primarily documented to present with nausea, vomiting, and diarrhea. The most severe risk, stemming from either massive acute exposure or chronic overexposure, is the potential for life-threatening renal failure and hepatic failure, according to official labeling.


Required Emergency Actions

Regulatory authorities mandate that any suspected or confirmed overdose is a medical emergency requiring immediate medical attention. This includes contacting a Poison Control Center or emergency services and ensuring hospital monitoring is initiated promptly.

No specific antidote is known for Allopurinol overdose, as explicitly stated in prescribing information. Management must therefore consist of symptomatic and supportive treatment. Procedural interventions noted in regulatory text include measures to maintain adequate diuresis to aid clearance and the potential use of hemodialysis to remove the drug and its metabolite in cases of severe intoxication.


Population Considerations

Official labeling notes that patients with pre-existing renal impairment are at an increased risk for severe toxicity due to impaired clearance of the drug’s metabolite, a factor magnified in an overdose scenario.

Therapeutic Uses of Puricemia

Puricemia is commonly used across therapeutic domains involving conditions where symptoms may intensify temporarily or present with systemic discomfort.

The medication is applied for easing symptoms across three therapeutic domains: chronic gout, recurrent uric acid kidney stones, and supportive care in certain cancer therapies. Its main benefit contributes to easing the overall symptom load associated with symptoms related to systemic imbalance.

Targeting Specific Symptom Clusters

This medication is primarily used for the long-term management of chronic gout, a condition characterized by periods of heightened symptoms, including intense joint pain and swelling. Puricemia is used to help address symptom clusters that become disruptive during flare-ups and may support the management of established tophi. It is also commonly used to help with managing symptoms associated with uric acid kidney stone formation and recurrence (nephrolithiasis) and is relevant for easing the risk of acute complications in certain high-risk metabolic scenarios.

“The medication is applied in managing conditions where additional symptomatic support is needed to address symptoms related to systemic imbalance.”

This provides a crucial therapeutic benefit by assisting with maintaining functional stability and supports patients during episodes of heightened discomfort.

Quick Fact: Scope includes Joint and Renal Conditions

Regulatory References

  1. NIH MedlinePlus overview on Allopurinol

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Puricemia

Puricemia is a medication used to reduce high levels of uric acid in the blood. Eligibility for its use is strictly defined by regulatory documents, which outline the populations who may use the drug and those who must avoid it.

Who Cannot Use Puricemia (Contraindications)

Use of Puricemia is contraindicated (prohibited) for anyone with a known history of hypersensitivity or a severe reaction (such as a severe skin rash) to the active ingredient or any component of the drug. The medication must be immediately discontinued at the first sign of a skin rash or other indication of a hypersensitivity reaction.

Populations with Use Restrictions

Population Eligibility Restriction
Pediatric Patients Safety and effectiveness have not been established for use in patients under 18 years old for conditions like gout and kidney stones.
Renal Impairment Requires special consideration and a lower starting dosage modification due to reduced clearance by the kidneys.
Hepatic Impairment Use requires caution and may necessitate dose adjustments due to potential effects on the liver.

Eligible Populations

Puricemia is indicated for use in adults with primary or secondary gout and recurrent calcium oxalate kidney stones, as well as in both adult and pediatric patients with high uric acid levels (hyperuricemia) associated with cancer therapy (e.g., chemotherapy for leukemia).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Puricemia has several documented interactions with other medicines, stemming primarily from its effect on metabolic enzymes. These interactions can significantly alter the exposure and effects of co-administered agents.

Contraindicated and Restricted Combinations

Co-administration of Puricemia with Pegloticase is officially contraindicated. Treatment with Puricemia must be stopped before initiating Pegloticase therapy due to the risk of reduced efficacy of Pegloticase.

Interactions Altering Drug Exposure

Puricemia inhibits the metabolism of purine analogs, such as Mercaptopurine and Azathioprine. This inhibition, which occurs via the enzyme Xanthine Oxidase, substantially increases the concentration of these co-administered agents. Regulatory guidance requires careful management of the dosage of the co-administered purine analog.

The regulatory label also indicates that Puricemia prolongs the plasma half-life of Vidarabine and the anticoagulant Dicumarol. Increased monitoring is required when Puricemia is used with these specific medicines.

Pharmacodynamic and Population-Specific Interactions

Uricosuric agents (e.g., Probenecid) can reduce the effectiveness of Puricemia by increasing the renal clearance of its active metabolite. Furthermore, in patients with decreased renal function, concomitant use of Puricemia and Thiazide Diuretics is associated with an increased risk of severe hypersensitivity reactions.

Mechanism of Action

Targeted Inhibition of the Uric Acid Production Enzyme

Puricemia exerts its effect by acting as a highly specific inhibitor of the Xanthine Oxidase (XO) enzyme, which is responsible for the final two steps of purine catabolism. The drug's active form, Oxypurinol, binds tightly to the enzyme's active site, forming a stable complex that stops the enzyme from converting hypoxanthine and xanthine into uric acid.


Cascade Leading to Crystal Dissolution

This molecular cascade, leading SUC to fall below the saturation point, results in a measurable and sustained reduction in the systemic concentration of uric acid (SUC). This reduction establishes the physiological gradient necessary for the dissolution of monosodium urate crystals from solid-state reservoirs. Concurrently, the inhibition enhances the purine salvage pathway, promoting the reutilization of precursors and diminishing their availability for catabolism.


️ Mechanism Limitations on Acute Inflammation

The drug's mechanism is confined to correcting the underlying metabolic imbalance; it does not modulate the pathways responsible for acute immune cell activation or inflammation. Furthermore, the necessary metabolic shift results in the accumulation and increased excretion of precursors like xanthine, which introduces a physiological constraint regarding their own solubility.

Dosage and Administration Information

How Puricemia is Used: Official Administration Guidelines

Puricemia (Allopurinol) is classified as a medicine for chronic management, with its administration governed by established protocols concerning the route, dosing, and patient condition. The primary administration is oral, though an intravenous (IV) route is used in specific, monitored hospital settings when oral intake is inappropriate.


Standard Dosage and Frequency

Treatment typically begins with a low initial dose (e.g., 100 mg once daily). The dosage is then adjusted in small, incremental steps, often weekly, until a target serum urate level is achieved. The standard adult maintenance dose ranges from 200 mg to 800 mg per day, and the maximum total daily intake is 800 mg. The oral medicine is generally taken once daily. However, for total doses exceeding 300 mg per day, the amount may be split into divided doses to enhance tolerability.


Contextual Use and Adjustments

The tablet is taken after meals to minimize potential gastrointestinal discomfort. A high fluid intake is maintained to promote adequate diuresis. The dosing regimen is dependent on renal function: a dose reduction is applied for patients with kidney impairment, with specific guidelines based on creatinine clearance. Additionally, Puricemia treatment is for long-term use and is not initiated during an acute gout flare, though it may be continued during one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Puricemia

Clinical Evidence for Chronic Gout and Tophi Management

Research on the use of Puricemia for conditions characterized by episodic manifestations like chronic gout is based on Randomized Controlled Trials (RCTs) and systematic reviews that tracked adults with established gout, including those with joint deposits (tophi). Studies monitored the concentration of uric acid in the blood and documented outcomes like the frequency of acute gout flares. Findings from these structured studies describe patterns related to measured lower uric acid levels, which is the primary biomarker. Some studies noted patterns related to a lower frequency of acute gout flares and documented changes in the size and presence of tophi over the longer term. However, it is not yet clear whether long-term data provides sufficient insight into structural outcomes or joint integrity over many decades.

Research on High Uric Acid Levels in Cancer Therapy

The evidence for using Puricemia in the context of high uric acid levels (hyperuricemia) associated with certain cancer treatments relies on retrospective observational studies and consensus reports. These research scenarios examined temporary physiological imbalance in both adult and pediatric patients undergoing chemotherapy. Findings describe consistent patterns of uric acid measurement maintenance during the short-term, acute phases of cancer treatment. Data show patterns related to maintaining uric acid levels, and research describes that its use was observed in studies tracking acute renal complications in high-risk patients. Follow-up durations were limited, mainly focusing on the immediate days or weeks surrounding chemotherapy.

Additional Research Areas and Evidence Gaps

Puricemia was studied for its relevance in trials related to recurrent kidney stone formation, with long-term prospective studies observing patterns related to the frequency of new stone episodes in appropriate populations. Research has also explored its use in special populations, including those with co-existing Chronic Kidney Disease (CKD) or Cardiovascular Disease (CVD), but findings were mixed across large trials and meta-analyses, meaning certainty remains low in these areas. Data are still emerging, and research has provided limited insight into whether its use over decades maintains the same level of measured effect on all tracked outcomes.

Key Studies & References

  1. Gout: diagnosis and management - NICE Guideline [NG219]
  2. Allopurinol for chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Puricemia (FAQ)

Q: Can people with kidney problems safely take Puricemia?

Use of Puricemia in individuals with kidney impairment requires special consideration. Because the medicine is cleared by the kidneys, dosage reduction is required for this population to help mitigate the risk of drug accumulation and adverse outcomes. Specific guidelines for dose adjustments are based on a person’s measured kidney function.

Q: Is Puricemia safe to take during pregnancy?

Official prescribing information states that data on the use of Puricemia in pregnant women do not demonstrate a clear pattern of negative developmental outcomes. It is generally not recommended during pregnancy. The decision to use it requires an assessment of the potential benefits versus the risks, as documented by regulatory agencies.

Q: What happens if I miss a dose of Puricemia?

Regulatory patient counseling information advises that if a dose of Puricemia is missed, you should not double the dose to make up for the missed one. The advice for a missed dose is to resume the normal schedule and take the next dose at the regularly scheduled time.

Q: Does alcohol consumption affect how Puricemia works?

While use is not strictly prohibited in regulatory warnings, official information advises that alcohol consumption may raise uric acid levels in the blood. Since Puricemia is intended to lower uric acid, drinking alcohol could potentially counteract the treatment’s effectiveness. Alcohol may also increase certain nervous system side effects like drowsiness.

Q: Are there any warnings about driving or operating machinery while taking Puricemia?

Due to the potential for effects like drowsiness, dizziness, or somnolence (sleepiness), official labeling advises caution regarding driving or operating hazardous machinery until a patient knows how the medication affects them.

Q: How quickly does Puricemia start to work after taking it?

Puricemia’s active substance has a rapid onset of action, with detectable levels appearing in the blood plasma quickly after administration. However, the full therapeutic effect of sustained uric acid reduction typically takes more time, often being measurable after 1 to 2 weeks of consistent use.

Q: How long does the effect of Puricemia last?

The active substance in Puricemia is processed into a metabolite that has a prolonged half-life (a measure of how long it stays in the body). This extended presence in the body allows the therapeutic effect of reducing uric acid production to be maintained with once-a-day dosing for many patients.

Q: What are the most common side effects of Puricemia that people report?

The most common adverse reaction, based on regulatory frequency classification, is a skin rash. Other reported effects, which are generally less frequent, can include gastrointestinal issues like nausea and vomiting, dizziness, and abnormal liver function test results.

Q: Is it normal to feel a bit dizzy when starting Puricemia?

Official safety data lists dizziness as a possible adverse reaction that has been reported by patients taking this medication. If this occurs, caution should be used with activities that require concentration.

Q: Does Puricemia cause weight gain or loss?

Weight loss has been mentioned in regulatory documents in the context of rare adverse reactions that may require further investigation, particularly if it occurs alongside other symptoms like loss of appetite. Weight gain is not specifically highlighted as a common side effect.

Q: Can Puricemia affect my sleep?

Yes, the official label includes central nervous system side effects such as drowsiness (somnolence) and difficulty sleeping (insomnia) in its list of reported adverse reactions. These effects may influence the normal sleep cycle.

Q: Can Puricemia be taken with common painkillers like ibuprofen?

Regulatory-associated patient information states that there are no known contraindications with common, non-prescription painkillers such as paracetamol or ibuprofen. However, all drug combinations should be reviewed by a healthcare provider.

Q: Are there any long-term side effects associated with Puricemia?

The highest risk for certain severe skin reactions is concentrated in the initial months of therapy. Official information notes that due to the potential for long-term effects on organs such as the kidneys and liver, periodic monitoring may be recommended.

Q: Is Puricemia known to cause any mood changes or depression?

Yes, adverse events affecting the central nervous system, such as depression, anxiety, and confusion, have been reported in post-marketing and rare case summaries for this medicine.

Q: Does Puricemia affect fertility?

Nonclinical toxicology studies in animal subjects have not indicated adverse effects on fertility.

Q: How often do the serious side effects of Puricemia occur?

Serious side effects, such as severe skin reactions like Stevens-Johnson syndrome (SJS), are categorized as rare. Other serious events involving the liver or blood are also classified as uncommon or rare in regulatory documents.

Q: Does Puricemia have any effect on liver function?

Yes, cases of reversible hepatotoxicity (liver damage) have been reported, and the medicine is known to potentially cause abnormal liver function test results. Official guidelines recommend evaluating liver function if signs of liver problems develop.

Q: Is Puricemia available in different strengths?

Yes, the tablets are officially available in different strengths to allow for titration (gradual adjustment) of the dosage based on individual needs and treatment goals. Common strengths typically include 100 mg and 300 mg tablets.

Q: Are there any specific vitamins or minerals that shouldn't be taken with Puricemia?

Official information advises patients to inform their healthcare provider about all supplements they are taking. It specifically notes that certain antacids that contain aluminum hydroxide should be taken with a time separation, such as three hours, before or after the Puricemia dose.

Q: Does Puricemia cause dry mouth?

Dry mouth has been reported as an adverse reaction in the post-marketing surveillance summaries for this medication, though it is not classified as a common event.

Q: Are there any foods I absolutely must avoid while taking Puricemia?

There are no specific foods listed in the official patient information that must be strictly avoided as contraindications. However, all patients are consistently advised to maintain a high fluid intake to promote adequate diuresis (urine flow) during treatment.

Q: Does Puricemia have a strong taste?

While regulatory reports do not describe the inherent taste of the tablet, a change in taste sensation (known as dysgeusia) has been reported as a possible adverse effect in some patients.

Q: Can I take Puricemia if I'm already taking a blood pressure medicine?

Official labeling states that co-administration with certain blood pressure medications, particularly Thiazide Diuretics and some ACE inhibitors, can increase the risk of severe adverse reactions. This necessitates careful clinical oversight.

Q: Why is my doctor prescribing the lower dose of Puricemia?

The initial dosage is often kept low and titrated slowly. This approach is recommended by regulatory guidelines to minimize the risk of adverse reactions, including gout flares and severe skin reactions, and is also required for patients with kidney impairment.

How should Puricemia be stored and disposed of?

How to Store and Dispose of Puricemia

The storage of Puricemia (allopurinol) tablets must strictly follow regulatory standards to ensure product stability and safety.

Storage Requirements

The medicine must be kept at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F). It is mandatory to store Puricemia in the original container, keep the container tightly closed, and protect the tablets from light and excessive moisture. Storage environments where the tablets could freeze are prohibited.

For safety, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Puricemia must be disposed of according to local regulatory requirements. Do not dispose of the tablets by flushing them down the toilet or pouring them down a drain, unless a regulated drug take-back program specifically advises this.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Puricemia found in:

A-Z Index: